Posted by Michael Wonder on 04 Jun 2018
Peptilogics receives qualified infectious disease product designation from FDA for lead compound PLG0206 as a treatment for prosthetic joint infection
2 June 2018 - Builds on PLG0206 studies published in Nature Scientific Reports.
Peptilogics today announced that its lead compound PLG0206 has been granted qualified infectious disease product designation by the U.S. FDA for the treatment of prosthetic joint infections.
PLG0206 was developed utilizing Peptilogics’ novel eCAP (engineered cationic antibiotic peptide) platform.
